IL6 and cancer: It remains possible, however, that CPT-driven IL-6 production in select cancer cells is independent of STING, and reliant on alternative pathways involving other innate immune sensors detecting DNA damage from the nucleus or the mitochondria (Burleigh et al., 2020; Tigano et al., 2021).